Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant.

BMJ case reports - 24 Aug 2020

Manthri Sukesh, Costello Patrick N, Krishnan Koyamangalath

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chronic Disease
Share to Exons
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins c-kit

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 32843387
DOI: 10.1136/bcr-2020-236447
PMCID: PMC7449486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chronic mast cell leukaemia with exon 9 KIT mutation A502_Y503dup: a rare imatinib responsive variant.PMID 32843387Read ↗

Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412Semantic proximity Read ↗

A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.Semantic proximity Read ↗

A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.Semantic proximity Read ↗

De novo leukemic variant of mast cell leukemia with KIT D816V.Semantic proximity Read ↗

Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.Semantic proximity Read ↗

Kit Mutations: New Insights and Diagnostic Value.Semantic proximity Read ↗

Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 <i>KIT</i> mutations and review of the literatureSemantic proximity Read ↗

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutationSemantic proximity Read ↗

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.Semantic proximity Read ↗

Detection of C-KIT Mutations in Systemic Mastocytosis: How, When and WhySemantic proximity Read ↗

<i>KIT</i> and MastocytosisSemantic proximity Read ↗

Novel, activating KIT-N822I mutation in familial cutaneous mastocytosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.